- Active Substance: Delta-sleep-inducing peptide
- Concentration: 2 mg
- Pack Size: vial
- Manufacturer: Ultima Pharmaceuticals
- Brand Name: DSIP
SKU: P286
Shipping From
Understanding Ultima-DSIP (Delta-sleep-inducing peptide) 2mg for Sleep and Stress Research
Ultima-DSIP, offered by Ultima Pharmaceuticals, contains 2mg per vial of Delta-sleep-inducing peptide (DSIP). This neuropeptide was first isolated from the diencephalon of rabbits undergoing electrically induced sleep and is being investigated in research settings for its potential role in sleep regulation, stress reduction, and other physiological processes.
Mechanism of Action
DSIP is believed to interact with various neurotransmitter systems in the brain, including GABAergic, serotonergic, and dopaminergic pathways, which are known to be involved in sleep and wakefulness. Research suggests it may promote slow-wave sleep (delta sleep), which is considered the deepest and most restorative stage of sleep. Additionally, studies have explored its potential anxiolytic (anti-anxiety) and stress-reducing effects.
Benefits
- Investigated for its potential to improve sleep quality and duration.
- Studied for its effects on reducing stress and anxiety levels.
- Research into its potential to modulate pain perception.
- Exploration of its possible role in regulating endocrine functions.
- Studies on its potential antioxidant properties.
Please note: The potential benefits listed above are based on preclinical and some limited clinical research and have not been fully established in humans for widespread therapeutic use. DSIP is a research compound and is not approved for human therapeutic use by regulatory authorities in many regions.
Usage Guidelines
As a research compound, any guidelines regarding its use are strictly within the context of laboratory and research settings. Administration protocols and dosages vary significantly depending on the specific research objectives and models. Common routes of administration in research include subcutaneous or intramuscular injection. Intranasal administration has also been explored in some studies. Any information regarding human dosage or administration is speculative and not recommended.
Potential Side Effects (Based on Research)
Research on DSIP has generally indicated a favorable safety profile in the studies conducted. Reported side effects have been minimal and often mild. However, the long-term safety profile and the full range of potential side effects are still under investigation.
FAQ
What is Ultima-DSIP (Delta-sleep-inducing peptide)?
Ultima-DSIP contains Delta-sleep-inducing peptide, a neuropeptide being researched for its potential role in sleep regulation and stress reduction.
How might DSIP affect sleep in research?
Research suggests it may promote slow-wave sleep (delta sleep), the deepest stage of restorative sleep.
What are the potential research benefits of DSIP?
Potential research benefits include improved sleep quality, reduced stress and anxiety, and potential modulation of pain perception.
What are the potential side effects observed in research?
Research has generally indicated a favorable safety profile with minimal and mild reported side effects.
Important Note: Ultima-DSIP (Delta-sleep-inducing peptide) is a research compound and is not approved for human therapeutic use by regulatory authorities in many regions. Information provided here is strictly for research and informational purposes only. It is not intended as a guide for personal use. The use of such compounds carries potential risks, and their long-term effects are not fully understood. Consult with qualified healthcare professionals for any health concerns.